Research and development of new potent antibodies
GLYCART biotechnology AG is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. GLYCART uses its proprietary set of technologies to endow therapeutic antibodies with competitive advantages.
The Company has developed glycoengineering technology (GlycoMAb®) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. In addition to GlycoMAb®, GLYCART has developed additional proprietary technologies covering all key elements of the monoclonal antibody value chain in order to streamline its product development efforts while minimizing potential royalty stacking.
Three preclinical programs for cancer
GLYCART currently has three proprietary lead antibody candidates in preclinical testing and has assembled internal and external capabilities both to develop and manufacture therapeutic antibodies. The Company’s technologies and products are protected by one issued US patent and more than 30 pending patent applications, including seven patent families.
Spin-off of ETH in Zürich
GLYCART was founded in September 2000 as a spin-off company from the Swiss Federal Institute of Technology in Zürich, Switzerland.
In July 2005 GLYCART was acquired by Roche and is now part of the Roche Research sites.
The Company currently has approximately 40 employees and is located in state-of-the-art facilities in Schlieren, the industrial area of Zürich, Switzerland.